Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00002184 | A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient | PHASE2 | COMPLETED | 120 | — | — | - | - | Jun 24, 2005 | 15 | United States, Puerto Rico |
| Name | Type | Description |
|---|---|---|
| Nelfinavir mesylate | DRUG | - |
| Levocarnitine | DRUG | - |
| Adefovir dipivoxil | DRUG | - |
| Saquinavir | DRUG | - |
| Lamivudine | DRUG | - |
| Stavudine | DRUG | - |
| Zidovudine | DRUG | - |
Inclusion Criteria Patients must have: * Laboratory diagnosis of HIV infection (positive HIV antibody test confirmed by Western blot, p24 antigen assay, HIV-1 RNA, or HIV-1 culture). * An HIV-1 RNA plasma titer \>= 5000 copies/ml within 14-21 days prior to the baseline visit. * CD4 cell count \>= ...